Stefan Dübel (German pronunciation: [ˈʃtɛfaːn ˈdyːbl̩]; born 13 January 1960 in Hanau, Hesse) is a German biologist. Since October 2002, he has been a full professor at the University of Braunschweig and head of the Biotechnology Department of the Institute of Biochemistry, Biotechnology and Bioinformatics.[1] His work is centred around protein engineering, phage display and recombinant antibodies.

Biography

edit

Dübel studied biology at the Johannes Gutenberg University in Mainz and at the Ruprecht-Karls University in Heidelberg from 1978 to 1983. He subsequently completed his civil service. From 1986 to 1989 he was promoted Dr. rer. nat. with a thesis titled: Cell Cycle Regulation and Cell Differentiation in the Coelenterate Hydra[2] at the Centre for Molecular Biology at the University of Heidelberg. Subsequently, he was a postdoctoral fellow at the German Cancer Research Center and at the Institute of Cell Biology and Immunology at the University of Stuttgart. From 1996 to 2001 he was group leader at the Department of Molecular Genetics at the University of Heidelberg, where he achieved his habilitation in the lab of Ekkehard Bautz in 1997. From 2001 to 2002 he was CSO of LifeBits AG.

Scientific work

edit

Dübel's most important work was, together with Frank Breitling, his contributions to the development of phage display for the production of human antibodies. He co-pioneered in vitro antibody selection technologies, resulting in several inventions including antibody phage display, human antibody libraries ) and antibody libraries with randomised CDRs. His lab continued to contribute multiple innovations to Recombinant antibodies, therapeutic antibodies, phage display, ORFeome display, animal-free antibody generation and in vitro evolution, e.g. Hyperphage technology (2001), ORFeome display (2006), and targeted RNases for cancer therapy (1995/2008). Further achievements include the development of the world's first protein knock down mouse using intrabodies (2014), a universal allosteric switch module for antibody affinity (2017) and multiclonal antibodies (2019). In 2020, he was one of the initiators of CORAT (Corona Antibody Team) which aims to cure COVID-19 with neutralizing antibodies against SARS-CoV-2.[3]

Awards and honours

edit

Bibliography

edit
  • Dübel, Stefan; Reichert, Janice M (2014). Handbook of therapeutic antibodies. Vol. 1 : Defining the right antibody composition (2nd ed.). Weinheim, Germany: Wiley Blackwell. ISBN 978-3-527-32937-3.
  • Dübel, Stefan; Reichert, Janice M (2014). Handbook of therapeutic antibodies. Vol. 2, Clinical development of antibodies (2nd ed.). Weinheim, Germany: Wiley Blackwell. ISBN 978-3-527-32937-3.
  • Dübel, Stefan; Reichert, Janice M (2014). Handbook of therapeutic antibodies Vol. 3. Approved therapeutic antibodies (2nd ed.). Weinheim, Germany: Wiley Blackwell. ISBN 978-3-527-32937-3.
  • Dübel, Stefan; Hust, Michael; Frenzel, André; Schirrmann, Thomas; Breitling, Frank (2019). Rekombinante Antikörper (in German) (2nd ed.). Berlin: Springer. ISBN 978-3-662-50275-4.

These are the top 5 most cited papers authored or co-author by Dübel:

References

edit
  1. ^ "Prof. Dr. Stefan Dübel". Department of Biotechnology Institute for Biochemistry, Biotechnology and Bioinformatics. Technische Universität Braunschweig. Retrieved 2 September 2020.
  2. ^ "Prof. Dr. Stefan Dübel". Faculty, Institut für Biochemie, Biotechnologie und Bioinformatik. Technische Universität Braunschweig. Retrieved 2 September 2020.
  3. ^ Bertoglio, Federico; Meier, Doris; Langreder, Nora; Steinke, Stephan; Rand, Ulfert; Simonelli, Luca; Heine, Philip Alexander; Ballmann, Rico; Schneider, Kai-Thomas; Roth, Kristian Daniel Ralph; Ruschig, Maximilian; Riese, Peggy; Eschke, Kathrin; Kim, Yeonsu; Schäckermann, Dorina; Pedotti, Mattia; Kuhn, Philipp; Zock-Emmenthal, Susanne; Wöhrle, Johannes; Kilb, Normann; Herz, Tobias; Becker, Marlies; Grasshoff, Martina; Wenzel, Esther Veronika; Russo, Giulio; Kröger, Andrea; Brunotte, Linda; Ludwig, Stephan; Fühner, Viola; Krämer, Stefan Daniel; Dübel, Stefan; Varani, Luca; Roth, Günter; Čičin-Šain, Luka; Schubert, Maren; Hust, Michael (11 March 2021). "SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface". Nature Communications. 12 (1). Springer Science and Business Media LLC: 1577. Bibcode:2021NatCo..12.1577B. doi:10.1038/s41467-021-21609-2. ISSN 2041-1723. PMC 7952403. PMID 33707427.
  4. ^ "Historical Awards" (PDF). American Association of Pharmaceutical Scientists. Innovation in Biotechnology Awards. Retrieved 2 September 2020.
  5. ^ "Die Gewinner". IHK Braunschweig (in German). Retrieved 2 September 2020.
  6. ^ "Innovationspreis für Forschung an Impfstoffentwicklung gegen Zecken". Technische Universität Braunschweig (in German). Blogs. 11 April 2019. Retrieved 2 September 2020.
  7. ^ "Innovationspreis Niedersachsen: Doppelpack für die Antikörperforschung". Technische Universität Braunschweig (in German). Blogs. 29 September 2020. Retrieved 29 September 2020.
  8. ^ "ECEAE Prize for animal-free antibodies: The winners". Blogs. 3 March 2022. Retrieved 3 March 2022.